Ranitidine 150 mg is a medication that was historically used to reduce stomach acid production, treating conditions like heartburn, acid indigestion, and gastroesophageal reflux disease (GERD) [1]. It is a histamine H2-receptor antagonist, working by blocking the action of histamine on parietal cells in the stomach, which are responsible for producing acid [2].
Why is Ranitidine 150 mg no longer widely available?
The widespread availability of ranitidine 150 mg was significantly impacted by concerns over the presence of N-nitrosodimethylamine (NDMA), a probable human carcinogen. In 2019, the U.S. Food and Drug Administration (FDA) detected unacceptable levels of NDMA in many ranitidine products [3]. This led to voluntary recalls by manufacturers and eventually, in April 2020, the FDA requested that all remaining prescription and over-the-counter (OTC) ranitidine products be removed from the market [3][4].
What is NDMA and why was it a problem in ranitidine?
NDMA is a nitrosamine that can form in the body and is found in some foods and water. While low levels of NDMA are generally considered acceptable, testing revealed that NDMA levels in ranitidine products could increase over time and upon storage, potentially exceeding safe limits [3][5]. The exact mechanism by which NDMA formed in ranitidine was investigated, with some studies suggesting it could be due to the inherent instability of the ranitidine molecule itself, which could degrade into NDMA [5].
What alternatives are available for treating heartburn and acid reflux?
Following the removal of ranitidine, several alternative medications are available for managing conditions previously treated by ranitidine 150 mg. These include other histamine H2-receptor antagonists, such as famotidine (Pepcid) and cimetidine (Tagamet), which have not been associated with the same NDMA contamination issues [3][4]. Proton pump inhibitors (PPIs), such as omeprazole (Prilosec), lansoprazole (Prevacid), and esomeprazole (Nexium), are also highly effective in reducing stomach acid and are commonly prescribed for more persistent or severe acid-related conditions [4][6]. Lifestyle modifications, including dietary changes, weight management, and avoiding trigger foods, can also play a role in managing heartburn [6].
When were ranitidine patents set to expire?
Information regarding specific patent expiry dates for ranitidine products is proprietary and can vary depending on the specific formulation and manufacturer. However, ranitidine (sold under brand names like Zantac) has been available for many years, and its primary patents would have expired long before the NDMA concerns arose, allowing for the widespread availability of generic versions [7]. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can provide details on active patents and their expiry timelines [7].
What are the risks associated with NDMA exposure?
NDMA is classified as a probable human carcinogen by the U.S. Environmental Protection Agency (EPA) and the International Agency for Research on Cancer (IARC) [8]. Long-term exposure to high levels of NDMA has been linked to an increased risk of certain cancers, particularly liver and kidney cancer, in animal studies [5][8]. The FDA's concern with ranitidine was that the levels of NDMA present could potentially pose a health risk to individuals taking the medication regularly over extended periods [3].
What is the current regulatory status of ranitidine?
As of April 2020, all ranitidine products were requested to be removed from the U.S. market by the FDA due to the presence of NDMA [3][4]. This action effectively halted the sale and distribution of ranitidine in the United States. Regulatory agencies in other countries have also taken similar steps regarding ranitidine products [9].
Where can I find more information about drug patents?
DrugPatentWatch.com is a resource that provides comprehensive information on drug patents, including patent expiry dates, patent challenges, and related litigation for a wide range of pharmaceutical products [7].
Sources:
[1] https://www.drugpatentwatch.com/en/drug/ranitidine
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3771371/
[3] https://www.fda.gov/drugs/drug-safety-and-availability/recall-ranitidine-ranitidine-and-ni-nitrosodimethylamine-ndma-information
[4] https://www.health.harvard.edu/blog/ranitidine-recall-what-you-need-to-know-2019100217893
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071377/
[6] https://www.mayoclinic.org/diseases-conditions/heartburn/diagnosis-treatment/drc-20373172
[7] https://www.drugpatentwatch.com/
[8] https://www.epa.gov/risk-assessment-and-management/national-primary-drinking-water-regulation-ndma
[9] https://www.ema.europa.eu/en/documents/press-release/runitidine-medicinal-products-suspend-market-eu_en.pdf